We sought to study the nature of rifampicin resistance in Pseudomonas aeruginosa. We hypothesized that the rifamycin regions of RNA polymerase are conserved in P. aeruginosa and that rifampicin resistance is mediated by a mutation in the rpoB gene encoding the /? subunit of RNA polymerase. Transcription assays showed that 50 nM of rifampicin inhibited transcription >99% in a clinical isolate (MIC = 32 mg/L) and only <40% in the rifampicin resistant mutant (MIC = 1000 mg/L). DNA sequencing revealed that the nfampicin regions are conserved in P. aeruginosa and the rifampicin regions of the rifampicin-resistant strain contained a mutation. Sodium hexametaphosphate lowered rifamycin MIC in a rifamycin-resistant mutant four-fold and in the clinical isolate 32-fold, suggesting that P. aeruginosa has a natural membrane barrier to rifamycins.
Introduction
Infections due to Pseudomonas aeruginosa are associated with higher mortality and morbidity than other bacteria even in the face of antibiotic therapy. The anti-pseudomonal treatment of choice has been the combination of aminoglycoside and a /?-lactam antibiotic. In an attempt to find more effective chemotherapy, rifampicin has been used as a component of multiple antibiotic therapy against P. aeruginosa and some success has been demonstrated in vitro (MIC), in vivo (animal models), and in randomized controlled trial (patients with P. aeruginosa bacteraemia) using a triple combination regimen of /J-lactam-aminoglycoside-rifampicin (Zuravleff, Yu & Yee, 1983; Zuravleff et al., 1984; Traub, Spohr, & Bauer, 1988; Valdes el al., 1990) . However, emergence of rifampicin resistance for numerous bacteria has been observed following rifampicin administration. The emergence of rifampicin-resistant P. aeruginosa could pose a potential problem. In addition, difference in the level of rifampicin inhibition between in-vitro transcription assays and in-vivo susceptibility tests has been attributed to a permeability barrier but has not yet been assessed using a membrane disrupter (Jin & Gross, 1988 rifampicin resistance is mediated by an altered /? subunit of RNA polymerase, which is encoded by the rpoB gene, the difference in the level of rifampicin inhibition between transcription assays and MIC results is attributed to a naturally occurring permeability barrier in P. aeruginosa, which can be neutralized with a subinhibitory concentration of sodium hexametaphosphate. In this report, we sought to determine whether (i) transcription in P. aeruginosa is inhibited by rifampicin and rifapentine, (ii) the rifamycin regions are conserved in P. aeruginosa, and (iii) sodium hexametaphosphate can lower the rifamycin MIC of a spontaneous laboratory rifampicin-resistant mutant.
Methods
P. aeruginosa strain 209 was isolated from a bacteraemic patient and strain 209A was derived from the clinical isolate by selection using Mueller-Hinton agar containing 100 mg/L of rifampicin. Reference strains P. aeruginosa ATCC 27107 and Escherichia coli K12 were used as controls in all experiments. Susceptibility testing was done according to NCCLS guidelines (NCCLS, 1993) . RNA polymerase, extracted from the bacterial strains, was measured for transcription activity in an in-vitro assay (Chamberlain et al., 1979) .
In our initial attempt to isolate the rpoB gene in P. aeruginosa for cloning into a vector by Southern blot restriction analysis, we were unable to identify a DNA fragment containing the entire gene, possibly because the restriction sites flanking rpoB might not be conserved in P. aeruginosa. We then resorted to direct thermocycling amplification of the rifamycin regions in genomic DNA using primers designed by sequence analysis of E. coli and Pseudomonas putida rifamycin regions. E. coli was chosen to design primers because its rpoB gene is well-characterized and could serve as a control. P. putida was chosen in the design of the oligonucleotides because priming would be more likely to succeed if the oligonucleotides were also designed using an organism phylogenetically related to P. aeruginosa. PCR using various primers and under conditions suggested by the manufacturer of Taq polymerase failed to generate DNA products in P. aeruginosa although, the control PCR, which contained E. coli genomic DNA, were successful. It was determined empirically that successful amplification of P. aeruginosa dsDNA by PCR required that the amount of time for denaturing be doubled from 5 to 10 min. A region encompassing the rifamycin regions in P. aeruginosa was cloned and sequenced using primers designed from homologous regions in the rpoB of E. coli and P. putida. A DNA fragment, amplified by PCR, encompassing the rifamycin regions was sequenced directly or cloned into a plasmid vector and then sequenced.
Results
According to NCCLS breakpoints, the clinical, ATCC 27107 and E. coli K12 strains were moderately susceptible to rifampicin and rifapentine (MIC = 32-64 mg/L) but strain 209A was highly resistant to rifampicin and rifapentine (MIC = 1000 mg/L). Rifapentine is a rifamycin with better pharmacokinetics than rifampicin.
Transcription by enzyme extracts of moderately susceptible strains was >99% inhibited by 50 nM of rifampicin and 50% inhibited by 100 nM of rifampicin, but •RNAP, RNA polymerase transcription by the rifampicin resistant strain was only <40% inhibited (Table) . Similar results were obtained with rifapentine (Data not shown). The DNA sequences (~800 bp) of the clinical isolate and the reference ATCC strain obtained by PCR sequencing were identical (Genbank ascension number M99386). Amino acid sequences of rifamycin regions of several bacteria were aligned in reference to the amino acid sequence of E. coli (Figure) . Figure. Alignment of known amino acid sequences of several bacteria with homology to the central portion of p. In E. coli the rpo B mutations conferring a spectrum of various levels of rifamycin resistance affect amino acids 507 to 533 (bold) in rifamycin region I, 563 to 572 (bold) in rifamycin region II, and codon 687 (bold) makes up rifamycin region III (Jin & Gross, 1988) . The amino acid sequence of P. aeruginosa is highly homologous with those of other bacteria. The amino acid sequence of the rifamycin regions is highly conserved among these bacteria with the exception of amino acid 531 (underlined). In the rifamycin resistant strain, a mutation occurs at codon 517 (D-»F) in rifamycin region I, which suggests that the mutation confers rifamycin resistance. Y. C. Yee et at. P. aeruginosa were highly homologous to Salmonella typhimurium (Genbank XI5849) and P. putida (Genbank X04642). A mutation (A->G) was sequenced in codon 517 in the nfampicin resistant strain. The position of this mutation is consistent with others that are known to lead to nfampicin resistance in E. coli and in clinical strains of Mycobacterium tuberculosis (Jin & Gross, 1988; Telenti et al., 1993) .
The addition of sodium hexametaphosphate to media used for susceptibility testing lowered the rifampicin and rifapentine MICs of the moderately susceptible strains from 32-64 to 0.5-1 mg/L and the rifampicin resistant strain from 1000 to 250 mg/L.
Discussion
Transcription by P. aeruginosa RNA polymerase was inhibited by rifampicin and rifapentine in vitro (Table) . Although the rpoB gene in P. aeruginosa was only partially sequenced, homology (> 80% nucleic acid identity) was found in the rifamycin regions between the obtained sequence and other bacteria to support the hypothesis that the sequenced mutation encodes rifamycin resistance in the rifampicin resistant mutant (Figure) . Furthermore, the site of the mutation in the rifampicin resistant mutant corresponded to the same site in rifampicin resistant E. coli and clinical isolates of M. tuberculosis (Jin & Gross, 1988; Telenti et al., 1993) . In fact, the MIC of these bacteria were also the same (1000 mg/L). The codons in the rifamycin regions among the bacteria in Figure were 93 .7% identical. This supports the hypothesis that mutations, which lead to rifampicin resistance, reside in the rifamycin regions. Guerrero et al. (1993) , however, have sequenced a mutation at codon 494 in Mycobacterium intracellulare with an rifampicin MIC of 4 mg/L but, codon 494 is considered outside the rifamycin regions.
Reduction of the MIC of the rifamycins by the addition of sodium hexametaphosphate in the susceptibility testing media of the clinical isolate suggests that the clinical isolate had an inherent low level permeability barrier to rifamycins. This is not surprising since naturally occurring P. aeruginosa isolates are commonly resistant or moderately susceptible to several classes of antibiotics because of its outer membrane (Nicas & Hancock, 1983) . The ratio of the reduced but highly rifampicin resistant mutant (1000 mg/L) and that of the moderately susceptible clinical isolate (MIC = 1 mg/L) was 250:1 (Table) . The ratio suggests that the altered RNA polymerase in the rifampicin resistant mutant plays a dominant role in resistance to rifamycins, while the natural permeability barrier in the clinical isolate and the mutant plays a lesser role. The permeability barrier might explain the difference between in-vitro and in-vivo results in rifampicin inhibition.
We conclude that high level rifamycin resistance in the laboratory mutant is mediated by a mutation in rpoB. The rifamycin regions are conserved in P. aeruginosa. Since the rifamycin regions are conserved in eubacteria, rifampicin resistant RNA polymerase such as those from well-described and less pathogenic E. coli might be used to screen compounds for activity against rifampicin resistant bacteria. Such a technique might reduce the risk in the handling and preparation of highly infectious bacteria (e.g. M. tuberculosis) for assaying transcription inhibitory agents. The difference in the level of rifampicin inhibition between in-vivo and in-vitro results is likely due to a permeability barrier mediated by the outer membrane.
